Chemomab Therapeutics Ltd Stock Market Value
| CMMB Stock | USD 1.71 0.01 0.58% |
| Symbol | Chemomab |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemomab Therapeutics. If investors know Chemomab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemomab Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Chemomab Therapeutics is measured differently than its book value, which is the value of Chemomab that is recorded on the company's balance sheet. Investors also form their own opinion of Chemomab Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Chemomab Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemomab Therapeutics' market value can be influenced by many factors that don't directly affect Chemomab Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemomab Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Chemomab Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemomab Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Chemomab Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Chemomab Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Chemomab Therapeutics.
| 10/26/2025 |
| 01/24/2026 |
If you would invest 0.00 in Chemomab Therapeutics on October 26, 2025 and sell it all today you would earn a total of 0.00 from holding Chemomab Therapeutics Ltd or generate 0.0% return on investment in Chemomab Therapeutics over 90 days. Chemomab Therapeutics is related to or competes with Kazia Therapeutics, Theriva Biologics, Elevai Labs, Can Fite, Biovie, XORTX Therapeutics, and InMed Pharmaceuticals. Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of i... More
Chemomab Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Chemomab Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Chemomab Therapeutics Ltd upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.22) | |||
| Maximum Drawdown | 21.68 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.48 |
Chemomab Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Chemomab Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Chemomab Therapeutics' standard deviation. In reality, there are many statistical measures that can use Chemomab Therapeutics historical prices to predict the future Chemomab Therapeutics' volatility.| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | (11.21) |
Chemomab Therapeutics January 24, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (11.20) | |||
| Mean Deviation | 3.52 | |||
| Coefficient Of Variation | (505.64) | |||
| Standard Deviation | 4.55 | |||
| Variance | 20.66 | |||
| Information Ratio | (0.22) | |||
| Jensen Alpha | (0.91) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | (11.21) | |||
| Maximum Drawdown | 21.68 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.48 | |||
| Skewness | 0.5314 | |||
| Kurtosis | 0.3564 |
Chemomab Therapeutics Backtested Returns
Chemomab Therapeutics secures Sharpe Ratio (or Efficiency) of -0.2, which signifies that the company had a -0.2 % return per unit of standard deviation over the last 3 months. Chemomab Therapeutics Ltd exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Chemomab Therapeutics' risk adjusted performance of (0.14), and Mean Deviation of 3.52 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.0811, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Chemomab Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Chemomab Therapeutics is expected to be smaller as well. At this point, Chemomab Therapeutics has a negative expected return of -0.86%. Please make sure to confirm Chemomab Therapeutics' potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if Chemomab Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.80 |
Very good predictability
Chemomab Therapeutics Ltd has very good predictability. Overlapping area represents the amount of predictability between Chemomab Therapeutics time series from 26th of October 2025 to 10th of December 2025 and 10th of December 2025 to 24th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Chemomab Therapeutics price movement. The serial correlation of 0.8 indicates that around 80.0% of current Chemomab Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.58 | |
| Residual Average | 0.0 | |
| Price Variance | 0.04 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Chemomab Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Chemomab Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Chemomab Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Chemomab Therapeutics Ltd Stock:Check out Chemomab Therapeutics Correlation, Chemomab Therapeutics Volatility and Chemomab Therapeutics Alpha and Beta module to complement your research on Chemomab Therapeutics. You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Chemomab Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.